GSK pulls back regulatory filing for mepolizumab in Europe

07/29/2009 | Reuters

GlaxoSmithKline withdrew its application in Europe for mepolizumab, an experimental treatment for hypereosinophilic syndrome, a blood disorder. The company, which wants to market the drug as Bosatria, said authorities would have requested additional data to prove the product's benefits.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD